Pharmaceutical company Johnson & Johnson announces their single-dose COVID-19 vaccine is 66% effective in preventing moderate disease and 85% in preventing severe disease during a global trial.
Pharmaceutical company Johnson & Johnson announces their single-dose COVID-19 vaccine was 66% effective in preventing moderate disease and 85% in preventing severe disease during a global trial.
Pharmaceutical company Johnson & Johnson announces their single-dose COVID-19 vaccine is 66% effective in preventing moderate disease and 85% in preventing severe disease during a global trial.